Company
Tg Therapeutics, INC
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
10
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Briumvi approved NovelDec 28, 2022
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPivotal-lookingRecruiting
TG Therapeutics, Inc.Industry
NCT05877963 · 800 participants (planned) · Start Jun 13, 2023 · Primary completion Jan 21, 2027
Drug: Ublituximab; Placebo · For: Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Orange, California · 51 sites in all
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisPivotal-lookingRecruiting
TG Therapeutics, Inc.Industry
NCT07220252 · 240 participants (planned) · Start Jul 1, 2026 · Primary completion Jan 1, 2030
Drug: Ublituximab; Placebo and 2 more · For: Relapsing Multiple Sclerosis
Sites: Salt Lake City, Utah; Gdansk, Poland; Poznan, Poland · 6 sites in all
Marketed drugs (1)
Newest FDA action first.
- Briumvi Ublituximab-Xiiy · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.